Memantine Protects Inflammation-Related Degeneration of Dopamine Neurons Through Inhibition of Over-Activated Microglia and Release of Neurotrophic Factors From Astroglia
This invention relates to a method of treating opiate addiction caused by microglial over-activation-mediated dopamine (DA) neurons damage, comprising administering a human in need of such treatment 0.01-0.08 mg/kg of 1-amino-3,5-dimethyladamantane hydrochloride orally per day.